|
1
|
Telaprevir for previously treated chronic HCV infection.
|
N Engl J Med
|
2010
|
8.33
|
|
2
|
Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.
|
Gastroenterology
|
2006
|
4.90
|
|
3
|
Burden of liver disease in the United States: summary of a workshop.
|
Hepatology
|
2002
|
4.00
|
|
4
|
An interferon-free antiviral regimen for HCV after liver transplantation.
|
N Engl J Med
|
2014
|
3.04
|
|
5
|
Serum sodium predicts mortality in patients listed for liver transplantation.
|
Hepatology
|
2005
|
2.63
|
|
6
|
Evidence-based incorporation of serum sodium concentration into MELD.
|
Gastroenterology
|
2006
|
2.62
|
|
7
|
Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model.
|
Cancer
|
2014
|
2.26
|
|
8
|
Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease.
|
Hepatology
|
2005
|
2.24
|
|
9
|
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.
|
Liver Transpl
|
2011
|
1.85
|
|
10
|
Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study.
|
Liver Transpl
|
2011
|
1.59
|
|
11
|
Alcohol use and hepatitis C.
|
Hepatology
|
2002
|
1.55
|
|
12
|
Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA).
|
J Clin Microbiol
|
2004
|
1.55
|
|
13
|
Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C.
|
Liver Transpl
|
2012
|
1.54
|
|
14
|
Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study.
|
Transplantation
|
2003
|
1.54
|
|
15
|
Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus.
|
Liver Transpl
|
2011
|
1.52
|
|
16
|
Trends in waiting list registration for liver transplantation for viral hepatitis in the United States.
|
Gastroenterology
|
2009
|
1.35
|
|
17
|
Outcomes of donor evaluation in adult-to-adult living donor liver transplantation.
|
Hepatology
|
2007
|
1.31
|
|
18
|
Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia.
|
Hepatology
|
2010
|
1.28
|
|
19
|
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.
|
Hepatology
|
2013
|
1.21
|
|
20
|
Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
|
Hepatology
|
2012
|
1.20
|
|
21
|
Limitations of conventionally derived chronic liver disease mortality rates: Results of a comprehensive assessment.
|
Hepatology
|
2008
|
1.17
|
|
22
|
Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study.
|
Am J Gastroenterol
|
2009
|
1.16
|
|
23
|
Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation.
|
Ann Surg
|
2010
|
1.13
|
|
24
|
New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection.
|
Liver Transpl
|
2004
|
1.11
|
|
25
|
The changing epidemiology and natural history of hepatitis C virus infection.
|
Clin Liver Dis
|
2006
|
1.11
|
|
26
|
Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men.
|
Hepatology
|
2011
|
1.09
|
|
27
|
Influence of cannabis use on severity of hepatitis C disease.
|
Clin Gastroenterol Hepatol
|
2008
|
1.08
|
|
28
|
Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.
|
Am J Transplant
|
2005
|
1.06
|
|
29
|
Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in.
|
Liver Transpl
|
2015
|
1.01
|
|
30
|
Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection.
|
Clin Gastroenterol Hepatol
|
2008
|
1.00
|
|
31
|
Management of hepatitis B in liver transplant recipients.
|
J Viral Hepat
|
2007
|
0.99
|
|
32
|
Characteristics and management of patients with chronic hepatitis B in an integrated care setting.
|
Dig Dis Sci
|
2014
|
0.96
|
|
33
|
Management of posttransplant hepatitis C infection.
|
Curr Opin Organ Transplant
|
2010
|
0.94
|
|
34
|
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
|
Gastroenterology
|
2013
|
0.92
|
|
35
|
Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy.
|
Liver Transpl
|
2011
|
0.92
|
|
36
|
Sex and hepatitis C.
|
Am J Gastroenterol
|
2005
|
0.92
|
|
37
|
Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma.
|
Liver Transpl
|
2012
|
0.91
|
|
38
|
Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis.
|
Clin Gastroenterol Hepatol
|
2005
|
0.91
|
|
39
|
The option of HBIG-free prophylaxis against recurrent HBV.
|
J Hepatol
|
2012
|
0.90
|
|
40
|
Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report.
|
J Med Case Rep
|
2009
|
0.90
|
|
41
|
Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease.
|
Liver Transpl
|
2006
|
0.88
|
|
42
|
Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.
|
Transplantation
|
2015
|
0.88
|
|
43
|
Progression of biopsy-measured liver fibrosis in untreated patients with hepatitis C infection: non-Markov multistate model analysis.
|
PLoS One
|
2011
|
0.88
|
|
44
|
Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study.
|
Liver Transpl
|
2012
|
0.88
|
|
45
|
Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity.
|
J Hepatol
|
2006
|
0.87
|
|
46
|
Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle.
|
Hepatology
|
2015
|
0.86
|
|
47
|
Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients.
|
Liver Transpl
|
2015
|
0.86
|
|
48
|
The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: results from population-based surveillance.
|
J Clin Gastroenterol
|
2010
|
0.85
|
|
49
|
Complementary and alternative medicine use in chronic liver disease patients.
|
J Clin Gastroenterol
|
2010
|
0.85
|
|
50
|
Hepatitis C genotype influences post-liver transplant outcomes.
|
Transplantation
|
2015
|
0.85
|
|
51
|
Ending vertical transmission of hepatitis B: the third trimester intervention.
|
Hepatology
|
2014
|
0.84
|
|
52
|
Donor Risk Index for African American liver transplant recipients with hepatitis C virus.
|
Hepatology
|
2013
|
0.84
|
|
53
|
Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander?
|
Dig Dis Sci
|
2015
|
0.83
|
|
54
|
Effects of ethnicity and socioeconomic status on survival and severity of fibrosis in liver transplant recipients with hepatitis C virus.
|
Liver Transpl
|
2012
|
0.83
|
|
55
|
Monocyte activation by interferon α is associated with failure to achieve a sustained virologic response after treatment for hepatitis C virus infection.
|
J Infect Dis
|
2013
|
0.82
|
|
56
|
Organ donors with positive viral serology or malignancy: risk of disease transmission by transplantation.
|
Transplantation
|
2002
|
0.82
|
|
57
|
Solid organ transplants in HIV-infected patients.
|
Curr HIV/AIDS Rep
|
2013
|
0.81
|
|
58
|
Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience.
|
Liver Transpl
|
2014
|
0.80
|
|
59
|
Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection.
|
Clin Infect Dis
|
2004
|
0.79
|
|
60
|
Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation.
|
Liver Transpl
|
2004
|
0.79
|
|
61
|
Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection.
|
Liver Transpl
|
2008
|
0.79
|
|
62
|
Non-Markov multistate modeling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplant.
|
Int J Biostat
|
2010
|
0.79
|
|
63
|
Older donors: mounting risks for the hepatitis C-infected liver transplant recipient?
|
Liver Transpl
|
2009
|
0.79
|
|
64
|
Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C.
|
Dig Dis Sci
|
2015
|
0.78
|
|
65
|
Treatment of recurrent hepatitis C after liver transplantation.
|
Clin Liver Dis
|
2005
|
0.78
|
|
66
|
Management of patients co-infected with HBV and HCV.
|
Expert Rev Anti Infect Ther
|
2009
|
0.77
|
|
67
|
Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective.
|
Liver Int
|
2015
|
0.77
|
|
68
|
Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years.
|
Clin Transplant
|
2006
|
0.77
|
|
69
|
Should HCV-related cirrhosis be a contraindication for retransplantation?
|
Liver Transpl
|
2003
|
0.76
|
|
70
|
Antiviral therapy in patients with chronic hepatitis B and cirrhosis.
|
Gastroenterol Clin North Am
|
2004
|
0.76
|
|
71
|
Perspectives on treating hepatitis C infection in the liver transplantation setting.
|
Curr Opin Organ Transplant
|
2016
|
0.75
|
|
72
|
Kidney and liver transplantation in HIV-infected patients: case presentations and review.
|
AIDS Patient Care STDS
|
2003
|
0.75
|
|
73
|
High Rate of Hospital Admissions Among Patients with Cirrhosis Seeking Care in US Emergency Departments.
|
Dig Dis Sci
|
2015
|
0.75
|
|
74
|
Individualizing hepatitis B infection prophylaxis in liver transplant recipients.
|
J Hepatol
|
2011
|
0.75
|
|
75
|
Chronic Hepatitis B.
|
Curr Treat Options Gastroenterol
|
2004
|
0.75
|
|
76
|
Reply to Prediction of hepatocellular carcinoma: using a complex risk model or assisting for smoking cessation?
|
Cancer
|
2014
|
0.75
|
|
77
|
Antiviral therapy in liver transplant recipients: is SVR the only endpoint that matters?
|
J Hepatol
|
2007
|
0.75
|
|
78
|
Prevalence and Predictors of Patient-Reported Long-Term Mental and Physical Health After Donation in the Adult to Adult Living Donor Liver Transplantation Cohort Study (A2ALL).
|
Transplantation
|
2017
|
0.75
|
|
79
|
Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection.
|
Infect Dis Clin North Am
|
2012
|
0.75
|
|
80
|
Management of recurrent hepatitis C in liver transplant recipients.
|
Infect Dis Clin North Am
|
2006
|
0.75
|
|
81
|
Understanding the natural history of chronic HBV and HCV infections.
|
J Fam Pract
|
2010
|
0.75
|
|
82
|
Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection.
|
Liver Transpl
|
2008
|
0.75
|
|
83
|
Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients.
|
Transplantation
|
2017
|
0.75
|
|
84
|
Pretransplant severe hepatic encephalopathy, peritransplant sodium and post-liver transplantation morbidity and mortality.
|
Liver Int
|
2011
|
0.75
|
|
85
|
Is recurrent hepatitis C worse with living donors?
|
Curr Opin Organ Transplant
|
2009
|
0.75
|